INTRODUCTION {#s1}
============

Breast conservation therapy (BCT) followed by radiotherapy is the standard of care for early-stage breast cancer. Previous studies have evaluated the outcomes of early-stage breast cancer patients without distinguishing between subtypes. However, breast cancer is a heterogeneous disease characterized by a wide spectrum of clinical, pathological, and molecular features \[[@R1], [@R2]\]. Importantly, the molecular subtypes can predict therapeutic response and prognosis.

Several studies have suggested that luminal A breast cancer has the best prognosis, whereas human epidermal growth factor receptor 2 (Her-2) and triple-negative breast cancer (TNBC) have higher rates of local recurrence \[[@R3]--[@R6]\]. However, other studies have reported no differences in pairwise comparisons between molecular subtypes \[[@R7], [@R8]\]. Because there is a low risk of local recurrence for early-stage breast cancer (≤ 5% at 5 years) \[[@R9]\], it is difficult to assess the association between molecular subtypes and local control. We performed a systematic review and meta-analysis to evaluate the efficacy of BCT followed by radiotherapy for the treatment of the four different molecular subtypes of breast cancer: luminal A, luminal B, Her-2, and TNBC.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

The study evaluation process is shown in Figure [1](#F1){ref-type="fig"}. A total of 1,232 titles were reviewed. Seven studies were selected for our meta-analysis \[[@R7], [@R8], [@R10]--[@R14]\], which included 3,798 luminal A, 770 luminal B, 344 Her-2, and 767 TNBC patients. The study characteristics are summarized in Table [1](#T1){ref-type="table"}.

![Flow chart depicting the study selection process](oncotarget-08-57414-g001){#F1}

###### Study characteristics

  Study                         Enrollment period   Population      Age (years)    Follow-up (months)   RT             CT     HT           Surgery                                                                                   
  ----------------------------- ------------------- --------------- -------------- -------------------- -------------- ------ ------------ -------------- --------------- -------------- --------------- --------- --------- ------- ------
  Arvold, 2011, USA             1997-2006           1103 (76.92%)   105 (7.32%)    55 (3.84%)           171 (11.92%)   1434   ≥55 47.0%    median: 85     median: 61 Gy   660 (46.03%)   1104 (76.99%)   T3 0.8%   N3 1.0%   30.5%   2.3%
  Demirci, 2012, USA            1985-2005           295 (66.59%)    75 (16.93%)    17 (3.84%)           56 (12.64%)    443    median: 56   median: 118    median: 62 Gy   66 (14.90%)    204 (46.05%)    T1-2      N0-1      nc      nc
  Hattangadi-Gluth, 2011, USA   1998-2003           937 (76.61%)    98 (8.01%)     52 (4.25%)           136 (11.12%)   1223   median: 55   median: 70.4   median: 60 Gy   558 (45.63%)   942 (77.02%)    T1-2      N3 1.1%   31.6%   3.9%
  Sanpaolo, 2011, Italy         2000-2008           361 (46.64%)    124 (16.02%)   134 (17.31%)         155 (20.03%)   774    median: 55   median: 59     median: 60 Gy   328 (42.38%)   186 (24.03%)    T1-2      N0-2      26.9%   9.0%
  Wong, 2011, Singapore         1989-2007           247 (59.81%)    76 (18.40%)    34 (8.23%)           56 (13.56%)    413    median: 49   median: 72     median: 60 Gy   194 (46.97%)   369 (89.35%)    T3 0.4%   nc        30.7%   4.8%
  Millar, 2009, Australia       1996-2003           394 (79.12%)    23 (4.62%)     13 (2.61%)           68 (13.65%)    498    median: 61   median: 84     50/61 Gy        117 (23.49%)   223 (44.78%)    T3 0.2%   N3 0.4%   29.1%   nc
  Bane, 2014, Canada            1993-1996           461 (51.57%)    269 (30.09%)   39 (4.36%)           125 (13.98%)   894    ≥50 73.6%    median: 144    42.5/50 Gy      110 (12.30%)   384 (42.95%)    T1-2      N0        20.0%   nc

RT: radiotherapy, CT: chemotherapy, HT: hormone therapy, nc: not clear.

Quality assessment {#s2_2}
------------------

The methodological quality of the included studies is shown in Table [2](#T2){ref-type="table"}. An independent assessment of outcome parameters was performed in two studies \[[@R8], [@R13]\]. Outcome parameters were unclear in five studies \[[@R7], [@R10]--[@R12], [@R14]\]. One study did not have clearly defined outcomes \[[@R12]\].

###### Methodology quality assessment

  Criteria                                                  Studies                       
  --------------------------------------------------------- --------- --- --- --- --- --- ---
  Clear definition of study population                      √         √   √   √   √   √   √
  Clear definition of outcomes and outcome assessment       √         ×   √   √   √   √   √
  Independent assessment of outcome parameters              ?         ?   √   ?   ?   √   ?
  Sufficient duration of follow-up                          √         √   √   √   √   √   √
  No selective loss during follow-up                        √         √   √   √   √   √   √
  Important confounders and prognostic factors identified   √         √   √   √   √   √   √

√: yes; ×: no; ?: not clear.

Meta-analysis {#s2_3}
-------------

The pooled odds ratios \[ORs\] for patients with the different molecular subtypes who were treated with BCT followed by radiotherapy are shown in Table [3](#T3){ref-type="table"}. The analysis of study heterogeneity and publication bias are also presented in Table [3](#T3){ref-type="table"}.

###### Pooled odds ratios for BCT followed by radiotherapy on different molecular subtypes of breast cancer

  Outcome        Comparison                Meta-analysis   Heterogeneity test   Model   Publication bias (p Value)                                              
  -------------- ------------------------- --------------- -------------------- ------- ---------------------------- ------- ------- -------- -------- -------- --------
  5-year LFS                                                                                                                                                    
                 Luminal A vs. luminal B   0.5221          0.2815-0.9684        2.06    0.0392                       0.00    3.39    0.4955   Fixed    0.8065   0.7773
                 Luminal A vs. Her-2       0.1960          0.0440-0.8728        2.14    0.0325                       79.98   19.98   0.0005   Random   0.8065   0.7624
                 Luminal A vs. TNBC        0.1731          0.0674-0.4444        3.65    0.0003                       73.14   14.89   0.0049   Random   0.0864   0.2480
                 luminal B vs. Her-2       0.4306          0.0741-2.5006        0.94    0.3478                       72.05   14.31   0.0064   Random   0.8065   0.1702
                 luminal B vs. TNBC        0.3588          0.0872-1.4755        1.42    0.1554                       69.43   13.09   0.0109   Random   1.0000   0.0232
                 Her-2 vs. TNBC            0.9483          0.5497-1.6357        0.19    0.8486                       24.92   5.33    0.2553   Fixed    0.4624   0.2496
  5-year LRFS                                                                                                                                                   
                 Luminal A vs. luminal B   0.4670          0.0610-3.5768        0.73    0.4635                       \-      \-      \-       Fixed    \-       \-
                 Luminal A vs. Her-2       0.1320          0.0310-0.5613        2.74    0.0061                       \-      \-      \-       Fixed    \-       \-
                 Luminal A vs. TNBC        0.1381          0.0565-0.3374        4.34    0.0000                       \-      \-      \-       Fixed    \-       \-
                 luminal B vs. Her-2       0.2826          0.0283-2.8247        1.08    0.2820                       \-      \-      \-       Fixed    \-       \-
                 luminal B vs. TNBC        0.2957          0.0400-2.1857        1.19    0.2325                       \-      \-      \-       Fixed    \-       \-
                 Her-2 vs. TNBC            1.0462          0.2586-4.2316        0.06    0.9495                       \-      \-      \-       Fixed    \-       \-
  10-year LFS                                                                                                                                                   
                 Luminal A vs. luminal B   0.5860          0.3422-1.0037        1.95    0.0516                       0.00    0.27    0.6048   Fixed    1.0000   \-
                 Luminal A vs. Her-2       0.2592          0.1301-0.5167        3.84    0.0001                       0.00    0.42    0.5177   Fixed    1.0000   \-
                 Luminal A vs. TNBC        0.6887          0.2341-2.0261        0.68    0.4981                       62.39   2.66    0.1030   Random   1.0000   \-
                 luminal B vs. Her-2       0.4434          0.2200-0.8938        2.27    0.0230                       0.00    0.80    0.3717   Fixed    1.0000   \-
                 luminal B vs. TNBC        1.6545          0.7414-3.6919        1.23    0.2189                       0.00    0.56    0.4555   Fixed    1.0000   \-
                 Her-2 vs. TNBC            2.6296          0.4828-14.3219       1.12    0.2636                       57.09   2.33    0.1269   Random   1.0000   \-
  10-year LRFS                                                                                                                                                  
                 Luminal A vs. luminal B   0.7707          0.2201-2.6986        0.41    0.6838                       0.00    0.53    0.4667   Fixed    1.0000   \-
                 Luminal A vs. Her-2       0.3354          0.0980-1.1484        1.74    0.0819                       0.00    0.04    0.8512   Fixed    1.0000   \-
                 Luminal A vs. TNBC        0.1221          0.0182-0.8192        2.17    0.0304                       86.40   7.35    0.0067   Random   1.0000   \-
                 luminal B vs. Her-2       0.5652          0.0899-3.5525        0.61    0.5430                       \-      \-      \-       Fixed    \-       \-
                 luminal B vs. TNBC        0.1502          0.0062-3.6671        1.16    0.2449                       76.24   4.21    0.0402   Random   1.0000   \-
                 Her-2 vs. TNBC            0.4448          0.0489-4.0442        0.72    0.4719                       54.42   2.19    0.1386   Random   1.0000   \-

The pooled OR for 5-year LFS for patients with luminal A compared to luminal B, Her-2, and TNBC was 0.5221 (95% confidence interval \[95% CI\]: 0.2815--0.9684, p = 0.0392), 0.1960 (95% CI: 0.0440--0.8728, p = 0.0325), and 0.1731 (95% CI: 0.0674--0.4444, p = 0.0003), respectively. The pooled OR for 10-year LFS for patients with luminal A compared to Her-2 breast cancer was 0.2592 (95% CI: 0.1301--0.5167, p = 0.0001). The pooled OR for 10-year LFS for patients with luminal B compared to Her-2 breast cancer was 0.4434 (95% CI: 0.2200--0.8938, p = 0.0230).

The pooled OR for 5-year LRFS for patients with luminal A compared to Her-2 and TNBC was 0.1320 (95% CI: 0.0310--0.5613, p = 0.0061) and 0.1381 (95% CI: 0.0565--0.3374, p = 0.0000), respectively. The pooled OR for 10-year LRFS for patients with luminal A compared to TNBC was 0.1221 (95% CI: 0.0182--0.8192, p = 0.0304). There were no differences in pairwise comparisons between the other groups.

DISCUSSION {#s3}
==========

The risk of local recurrence risk in patients with early-stage breast cancer is primarily assessed based on clinicopathological factors. We demonstrated that patients with the luminal A subtype have a better prognosis than those with the Her-2 subtype following BCT and radiotherapy. Thus, the different molecular subtypes are associated with distinct local control rates and can predict prognosis.

Although breast cancer patients are widely classified into the luminal A, luminal B, Her-2, and TNBC molecular subtypes in clinical practice \[[@R6], [@R15]\], these subtypes are only an approximation of the underlying genotype-based subtypes. A previous study suggested that a fraction of luminal B patients were misclassified as luminal A, because only 30--50% of patients classified as luminal B by genotyping were Her-2+ \[[@R6]\]. However, genetic analysis is often impractical in clinical practice because of the time and expense required. Therefore, clinicians routinely make treatment decisions based on classic prognostic factors.

The overall quality of the studies in our meta-analysis was moderate-to-high. The independent assessment of outcome parameters was unclear in five studies \[[@R7], [@R10]--[@R12], [@R14]\], which was the main source of bias in our analysis. However, independent assessment was not necessarily needed for the included studies because local recurrence is an objective outcome that is defined by pathology and imaging.

Our meta-analysis suggests that Her-2 patients have increased odds of 5- and 10-year LFS compared to luminal A patients. Trastuzumab is the preferred treatment for Her-2+ (luminal B and Her-2) patients. It has been shown to improve overall survival in Her-2+ patients with early-stage breast cancer \[[@R16]\]. However, local recurrence was not assessed \[[@R17], [@R18]\]. Sanpaolo et al. \[[@R7]\] reported similar local control rates for Her-2 and luminal A patients treated with trastuzumab. However, some studies have reported that trastuzumab did not affect the rate of local relapse in Her-2 patients, and there was no difference in local recurrence between patients with the Her-2 and luminal A subtypes \[[@R8], [@R19], [@R20]\]. Only two studies included in our meta-analysis analyzed patients treated with trastuzumab (87.3% had Her-2 type breast cancer in the Sanpaolo et al. study \[[@R7]\] and one had Her-2 breast cancer in the Wong et al. study \[[@R14]\]). Trastuzumab therapy was not administered to Her-2 patients in the other five studies \[[@R8], [@R10]--[@R13]\]. The observed differences in LFS between Her-2 and luminal A patients in our meta-analysis could be explained by the treatment of Her-2 patients with adjuvant trastuzumab therapy.

A previous meta-analysis demonstrated that the 5-year local control rate of TNBC patients was similar to that of non-TNBC patients \[[@R21]\]. In this study, TNBC patient outcomes were not analyzed according to subtype. Our meta-analysis suggests that TNBC patients had lower LRFS compared to luminal A patients. The increased risk of local-regional recurrence in TNBC patients may be correlated with the aggressive clinicopathological features and ineffectiveness of endocrine therapy or trastuzumab. There is insufficient data regarding the relationship between luminal B, Her-2, and TNBC and the risk of local recurrence. Our meta-analysis indicated there were no differences between patients with luminal B, Her-2, and TNBC.

Most local recurrences of breast cancer occur during the first 5 years following BCT and radiotherapy \[[@R22]\]. Our meta-analysis suggests that the local-regional control rate is higher in patients with the luminal A compared to Her-2 and TNBC. However, it is unclear whether local recurrence reflected inadequate patient selection/inadequate local treatment or aggressive disease. Her-2 and TNBC are associated with substantially higher rates of local-regional recurrence, suggesting that these subtypes are more aggressive than the luminal A subtype. Trastuzumab therapy for Her-2 patients may reduce the rate of local-regional recurrence. There are currently no effective therapies for TNBC.

Our meta-analysis had several limitations. First, the surgical approach and treatments (e.g. chemotherapy and hormone therapy) differed between studies. Some studies included patients with a positive margin and stage T3/N3 disease. The percent of patients who received chemotherapy and hormone therapy varied between studies. Second, our sample size was limited. This is because there is a low risk of local recurrence in early-stage breast cancer patients.

In conclusion, breast cancer molecular subtypes predict outcomes and treatment response in early-stage breast cancer patients treated with BCT followed by radiotherapy. Our results should be validated in patients with Her-2+ breast cancer treated with trastuzumab.

MATERIALS AND METHODS {#s4}
=====================

Study design {#s4_1}
------------

Our study was performed in accordance with the Meta-analysis of Observational Studies in Epidemiology \[[@R23]\] and PRISMA guidelines \[[@R24]\].

Selection criteria {#s4_2}
------------------

Studies that assessed the efficacy of BCT followed by radiotherapy in breast cancer patients were reviewed. The inclusion criteria were (1) invasive breast cancer treated with BCT followed by radiotherapy, (2) complete data on breast cancer molecular subtype, and (3) at least one outcome report (i.e. local relapse-free survival \[LFS\]), local-regional relapse-free survival (LRFS), or sufficient information to calculate LFS or LRFS. The exclusion criteria were (1) ductal carcinoma in situ, (2) incomplete data on molecular subtype, and (3) incomplete data on BCT or radiotherapy.

Breast cancer patients were classified into the following four groups based on estrogen receptor (ER), progesterone receptor (PR), and Her-2 status: luminal A (ER+ and/or PR+ and Her-2-), luminal B (ER+ and/or PR+, and Her-2+), Her-2 (ER- and PR-, and Her-2+), and TNBC (ER-, PR-, and Her-2-) \[[@R6], [@R15]\]. Because BCT and radiotherapy mainly provide local control, the endpoints of our meta-analysis were LFS and LRFS.

Data sources and queries {#s4_3}
------------------------

We searched the MEDLINE, EMBASE, and Cochrane Library databases to identify relevant studies completed before April 30, 2016. Search terms included 'breast cancer', 'breast conservation therapy', 'radiotherapy', and 'molecular subtype'. Article reference lists were also reviewed to identify additional studies. No language restrictions were imposed.

Study selection and quality assessment {#s4_4}
--------------------------------------

Study selection, data extraction, and quality assessment were performed by two independent investigators. Differences were resolved through discussion with a third investigator. Quality assessment was performed according to Hayden et al. \[[@R25]\]. Study quality and risk of bias were assessed based on the following criteria: (1) clear definition of study population, (2) clear definition of outcomes and outcome assessment, (3) independent assessment of outcome parameters, (4) sufficient duration of follow-up, (5) no selective loss during follow-up, and (6) important confounders and prognostic factors identified.

Statistical analysis {#s4_5}
--------------------

Cochran Q tests and I^2^ statistics were used to assess study heterogeneity, where a *p* \< 0.05 and I^2^ \> 50% were indicative of significant heterogeneity. A random-effects model was selected if heterogeneity was present and a fixed-effects model was selected in the absence of significant heterogeneity. Publication bias was evaluated using a funnel plot of trial effect size vs. standard error \[[@R26], [@R27]\]. All statistical analyses were performed using STATA version 12.0 (STATA, College Station, TX, USA).
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